Ryvu Therapeutics Announces Dosing of the First Patient in the JASPIS-01 Phase II Study of Dapolsertib (MEN1703/SEL24) for the Treatment of R/R DLBCL

Ryvu Therapeutics annnounced that the first patient has been dosed in the JASPIS-01 study, a Phase II clinical trial investigating dapolsertib for the treatment of patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).